display ongoing
results: demonstrated suggested inconclusive safety concern ongoing study
breast cancer - triple negative
la/mBC - TNBC - L1 - all populationla/mBC - TNBC - L1 - PDL1 positivees-BC - TNBC - NA - all population
pembrolizumab plus SoC KEYNOTE-355 ... KEYNOTE-355 ... KEYNOTE-355 ... KEYNOTE-522

Study type: